992,760 Veracyte, Inc. $VCYT Shares Acquired by GW&K Investment Management LLC

GW&K Investment Management LLC lifted its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 70.1% in the third quarter, HoldingsChannel reports. The firm owned 2,409,303 shares of the biotechnology company’s stock after acquiring an additional 992,760 shares during the period. Veracyte makes up about 0.9% of GW&K Investment Management LLC’s portfolio, making the stock its 9th biggest holding. GW&K Investment Management LLC’s holdings in Veracyte were worth $110,924,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of VCYT. Focus Advisor Solutions LLC lifted its holdings in Veracyte by 22.5% in the 3rd quarter. Focus Advisor Solutions LLC now owns 4,929 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 906 shares in the last quarter. Boston Partners purchased a new stake in shares of Veracyte during the third quarter worth about $30,357,000. Public Sector Pension Investment Board raised its position in shares of Veracyte by 43.5% in the third quarter. Public Sector Pension Investment Board now owns 501,437 shares of the biotechnology company’s stock valued at $21,802,000 after buying an additional 152,012 shares during the last quarter. Cibc World Market Inc. raised its position in shares of Veracyte by 6.0% in the third quarter. Cibc World Market Inc. now owns 53,521 shares of the biotechnology company’s stock valued at $2,464,000 after buying an additional 3,037 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky raised its position in shares of Veracyte by 1.3% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 52,765 shares of the biotechnology company’s stock valued at $2,429,000 after buying an additional 695 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have weighed in on VCYT shares. Canaccord Genuity Group cut their price target on Veracyte from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Needham & Company LLC decreased their price objective on Veracyte from $69.00 to $46.00 and set a “buy” rating on the stock in a report on Thursday, November 5th. Wall Street Zen downgraded Veracyte from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Leerink Partners lowered Veracyte from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $55.00 to $35.00 in a research note on Thursday, November 5th. Finally, UBS Group reduced their target price on Veracyte from $65.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $44.50.

Get Our Latest Research Report on VCYT

Insider Buying and Selling

In related news, CFO Rebecca Chambers sold 3,652 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $43.10, for a total transaction of $157,401.20. Following the transaction, the chief financial officer directly owned 166,025 shares in the company, valued at $7,155,677.50. This trade represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Leite sold 4,015 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $40.00, for a total value of $160,600.00. Following the transaction, the insider owned 124,329 shares in the company, valued at $4,973,160. This trade represents a 3.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 62,609 shares of company stock worth $2,858,904. 1.60% of the stock is currently owned by insiders.

Veracyte Price Performance

Shares of VCYT opened at $25.04 on Friday. Veracyte, Inc. has a 12 month low of $21.91 and a 12 month high of $60.91. The stock’s 50-day moving average is $40.72 and its two-hundred day moving average is $42.16. The stock has a market cap of $2.02 billion, a PE ratio of 16.82 and a beta of 1.98.

Veracyte (NASDAQ:VCYT – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.10. The company had revenue of $151.75 million for the quarter, compared to the consensus estimate of $147.13 million. Veracyte had a return on equity of 8.99% and a net margin of 21.80%. Veracyte’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.51 EPS. On average, research analysts anticipate that Veracyte, Inc. will post 1.34 earnings per share for the current year.

About Veracyte

(Free Report)

Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.

Featured Stories

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Free Report).

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.